Sundus S. Lateef
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sundus S. Lateef has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Marcus Y. Chen
National Heart Lung and Blood Institute, NIH, Bethesda, MD, USA
6 shared publications - Nehal Nikhilesh Mehta
The George Washington University School of Medicine, Washington, D.C., USA
6 shared publications - Wunan Zhou
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
5 shared publications - Alexander V. Sorokin
Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
4 shared publications - Christin G. Hong
Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
4 shared publications - Martin Peter Playford
Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
4 shared publications
Latest Publications
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (3) , e250079
Silicosis Epidemic among Engineered Stone Countertop Workers: Pictorial Review
Silicosis, once considered a historical occupational disease, has re-emerged with the fabrication of engineered stone countertops and is linked to complications such as progressive massive fibrosis and pneumothorax.
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (3) , e250079
Silicosis Epidemic among Engineered Stone Countertop Workers: Pictorial Review
Silicosis, once considered a historical occupational disease, has re-emerged with the fabrication of engineered stone countertops and is linked to complications such as progressive massive fibrosis and pneumothorax.
- 28 May 2025
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 28 (11) , 1342-1359
Hypothalamic regulated physiological function and gene expression changes suggest high fructose corn syrup intake affects neurodevelopment in adolescent female rats
To investigate the impact of drinking different caloric sweeteners from immaturity to young adulthood on hypothalamic controlled physiological functions and hypothalamic global gene expression using a rat model. Young female Sprague-Dawley rats (age 28 days) were randomly assigned (n = 7 rats/group) to drink water sweetened with 13% (w/w) sugar as either high fructose corn syrup (HFCS), sucrose, fructose, or water (control) for 8 weeks. Hypothalamic controlled physiological function measurements included: energy intake, stress, and estrous cycles. RNA-sequencing (RNA-Seq) was used to investigate global differentially expressed genes (DEGs) in the hypothalamus. Rats drinking HFCS and sucrose solution increased liquid intake, but reduced food intake. Rats drinking HFCS had the highest (p < 0.05) absolute adrenal weight, which is indicative of chronic stress, and had lengthened estrous cycles. The DEGs with the highest fold changes in the hypothalamus of rats drinking HFCS compared to sucrose and fructose were involved in circadian sleep cycles, neuronal processes, and Engrailed-2 (En2) identified in autism spectrum disorder (ASD). Among the different caloric-sweetened solutions, young female rats drinking HFCS solution showed food selectivity, elevated basal stress, and reproductive irregularity, which are characteristics associated with ASD. RNA-Seq revealed DEGs in rats drinking HFCS solution, included disrupted circadian sleep cycles, neurotoxicity, and ASD. The results of this preclinical study suggest that HFCS intake should be limited due to its potential for increasing the risk of neurodevelopmental disorders.
- 28 May 2025
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 28 (11) , 1342-1359
Hypothalamic regulated physiological function and gene expression changes suggest high fructose corn syrup intake affects neurodevelopment in adolescent female rats
To investigate the impact of drinking different caloric sweeteners from immaturity to young adulthood on hypothalamic controlled physiological functions and hypothalamic global gene expression using a rat model. Young female Sprague-Dawley rats (age 28 days) were randomly assigned (n = 7 rats/group) to drink water sweetened with 13% (w/w) sugar as either high fructose corn syrup (HFCS), sucrose, fructose, or water (control) for 8 weeks. Hypothalamic controlled physiological function measurements included: energy intake, stress, and estrous cycles. RNA-sequencing (RNA-Seq) was used to investigate global differentially expressed genes (DEGs) in the hypothalamus. Rats drinking HFCS and sucrose solution increased liquid intake, but reduced food intake. Rats drinking HFCS had the highest (p < 0.05) absolute adrenal weight, which is indicative of chronic stress, and had lengthened estrous cycles. The DEGs with the highest fold changes in the hypothalamus of rats drinking HFCS compared to sucrose and fructose were involved in circadian sleep cycles, neuronal processes, and Engrailed-2 (En2) identified in autism spectrum disorder (ASD). Among the different caloric-sweetened solutions, young female rats drinking HFCS solution showed food selectivity, elevated basal stress, and reproductive irregularity, which are characteristics associated with ASD. RNA-Seq revealed DEGs in rats drinking HFCS solution, included disrupted circadian sleep cycles, neurotoxicity, and ASD. The results of this preclinical study suggest that HFCS intake should be limited due to its potential for increasing the risk of neurodevelopmental disorders.
- Open Access
- 3 November 2023
- Published by Elsevier in JID Innovations
- Vol. 4 (1) , 100243
Circulating Oxidized mtDNA is Associated Broadly with Cardiovascular Disease in a Longitudinal Cohort Study of Psoriasis
- 3 November 2023
- Published by Elsevier in JID Innovations
- Vol. 4 (1) , 100243
Open AccessCirculating Oxidized mtDNA is Associated Broadly with Cardiovascular Disease in a Longitudinal Cohort Study of Psoriasis
- 21 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2909-2919
Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study
- 21 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2909-2919
Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study
- 8 June 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (6)
Cover Image: Volume 45 Issue 6
The cover image is based on the Full Article Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study by Nehal N Mehta et al., https://doi.org/10.1002/clc.23808.
- 8 June 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (6)
Cover Image: Volume 45 Issue 6
The cover image is based on the Full Article Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study by Nehal N Mehta et al., https://doi.org/10.1002/clc.23808.
- Open Access
- 2 April 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (6) , 622-628
Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study
Background Statin treatment is a potent lipid-lowering therapy associated with decreased cardiovascular risk and mortality. Recent studies including the PARADIGM trial have demonstrated the impact of statins on promoting calcified coronary plaque. Hypothesis The degree of systemic inflammation impacts the amount of increase in coronary plaque calcification over 2 years of statin treatment. Methods A subgroup of 142 participants was analyzed from the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study (NCT01212900), who were on statin treatment and underwent cardiac computed tomography angiography (CCTA) at baseline and 2-year follow-up. This cohort was stratified by baseline median levels of high-sensitivity hs-CRP and analyzed with linear regressions using Stata-17 (StataCorp). Results In the high versus low hs-CRP group, patients with higher baseline median hs-CRP had increased BMI (median [IQR]; 29 [27-31] vs. 27 [24-28]; p < .001), hypertension (59% vs. 41%; p = .03), and LDL-C levels (97 [77-113] vs. 87 [75-97] mg/dl; p = .01). After 2 years of statin treatment, the high hs-CRP group had significant increase in dense-calcified coronary burden versus the low hs-CRP group (1.27 vs. 0.32 mm(2) [100x]; p = .02), beyond adjustment (beta = .2; p = .03). Conclusions Statin treatment over 2 years associated with a significant increase in coronary calcification in patients with higher systemic inflammation, as measured by hs-CRP. These findings suggest that systemic inflammation plays a role in coronary calcification and further studies should be performed to better elucidate these findings.
- 2 April 2022
- Published by Wiley in Clinical Cardiology
- Vol. 45 (6) , 622-628
Open AccessInflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study
Background Statin treatment is a potent lipid-lowering therapy associated with decreased cardiovascular risk and mortality. Recent studies including the PARADIGM trial have demonstrated the impact of statins on promoting calcified coronary plaque. Hypothesis The degree of systemic inflammation impacts the amount of increase in coronary plaque calcification over 2 years of statin treatment. Methods A subgroup of 142 participants was analyzed from the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study (NCT01212900), who were on statin treatment and underwent cardiac computed tomography angiography (CCTA) at baseline and 2-year follow-up. This cohort was stratified by baseline median levels of high-sensitivity hs-CRP and analyzed with linear regressions using Stata-17 (StataCorp). Results In the high versus low hs-CRP group, patients with higher baseline median hs-CRP had increased BMI (median [IQR]; 29 [27-31] vs. 27 [24-28]; p < .001), hypertension (59% vs. 41%; p = .03), and LDL-C levels (97 [77-113] vs. 87 [75-97] mg/dl; p = .01). After 2 years of statin treatment, the high hs-CRP group had significant increase in dense-calcified coronary burden versus the low hs-CRP group (1.27 vs. 0.32 mm(2) [100x]; p = .02), beyond adjustment (beta = .2; p = .03). Conclusions Statin treatment over 2 years associated with a significant increase in coronary calcification in patients with higher systemic inflammation, as measured by hs-CRP. These findings suggest that systemic inflammation plays a role in coronary calcification and further studies should be performed to better elucidate these findings.
- 1 April 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (4) , 913-916
Impaired Coronary Blood Flow in Patients with Psoriasis: Findings from an Observational Cohort Study
- 1 April 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (4) , 913-916
Impaired Coronary Blood Flow in Patients with Psoriasis: Findings from an Observational Cohort Study